Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Clin Oncol ; 2(3): 157-63, 1984 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-6230422

RESUMO

Thirty-two women with advanced local regional breast carcinoma, including nine patients with histologically diagnosed inflammatory cancer, were entered on a prospective pilot study. They were treated aggressively with initial surgery, two courses of induction chemotherapy with cyclophosphamide, methotrexate, 5-fluorouracil, +/- prednisone, +/- tamoxifen (CMF [P] [T]), local-regional radiotherapy, and then maintenance chemotherapy with CMF(P) (T) alternating with doxorubicin, vincristine, +/- tamoxifen (AV[T]). The patients have been followed for 19-70 months from the time of mastectomy and their actuarial three-year survival is 65% with a median survival that has not yet been reached. Median disease-free survival (time to progression) is currently 29.5 months. Women whose gross disease could not be totally resected surgically had shorter disease-free survivals than those rendered surgically free of disease (p = 0.01). Clinically evident cardiotoxicity was seen in 25% of the patients and was felt to be primarily due to the combination of doxorubicin and radiation therapy. It was significantly more common (Plt less than 0.05) in patients with left chest irradiation (seven of 18 women) as opposed to those with right-sided irradiation (one of 14).


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/terapia , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias da Mama/mortalidade , Neoplasias da Mama/patologia , Cardiomegalia/induzido quimicamente , Terapia Combinada , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Fluoruracila/administração & dosagem , Fluoruracila/efeitos adversos , Seguimentos , Insuficiência Cardíaca/induzido quimicamente , Humanos , Mastectomia , Metotrexato/administração & dosagem , Metotrexato/efeitos adversos , Pessoa de Meia-Idade , Projetos Piloto , Prednisona/administração & dosagem , Prednisona/efeitos adversos , Estudos Prospectivos
2.
J Neural Eng ; 9(1): 016007, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22183300

RESUMO

We investigated the relationships of the firing rate and maximal recruitment threshold of motoneurons recorded during isometric contraction with the number of spindles in individual muscles. At force levels above 10% of maximal voluntary contraction, the firing rate was inversely related to the number of spindles in a muscle, with the slope of the relationship increasing with force. The maximal recruitment threshold of motor units increased linearly with the number of spindles in the muscle. Thus, muscles with a greater number of spindles had lower firing rates and a greater maximal recruitment threshold. These findings may be explained by a mechanical interaction between muscle fibres and adjacent spindles. During low-level (0% to 10%) voluntary contractions, muscle fibres of recruited motor units produce force twitches that activate nearby spindles to respond with an immediate excitatory feedback that reaches maximal level. As the force increases further, the twitches overlap and tend towards tetanization, the muscle fibres shorten, the spindles slacken, their excitatory firings decrease, and the net excitation to the homonymous motoneurons decreases. Motoneurons of muscles with greater number of spindles receive a greater decrease in excitation which reduces their firing rates, increases their maximal recruitment threshold, and changes the motoneuron recruitment distribution.


Assuntos
Potenciais de Ação/fisiologia , Retroalimentação Sensorial/fisiologia , Contração Isométrica/fisiologia , Neurônios Motores/fisiologia , Fusos Musculares/fisiologia , Músculo Esquelético/fisiologia , Recrutamento Neurofisiológico/fisiologia , Animais , Simulação por Computador , Humanos , Modelos Biológicos , Músculo Esquelético/inervação
4.
Radiology ; 122(2): 469-72, 1977 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-834897

RESUMO

Multiple drugs, a single drug, and irradiation were compared in patients with Stage III ovarian carcinoma. The results were categorized as "favorable" [pelvic mass less than 8 cm and/or upper abdominal tumor nodule(s) less than 2 cm] or "unfavorable" (more massive disease). A total of 62 patients are reviewed of whom 25 had irradiation and 37 had chemotherapy. It was found that patients with slight residual disease after celiotomy did equally well with either irradiation or chemotherapy, but survival was improved using a combination of both. Use of 5 drugs did not significantly improve survival beyond that obtained with a single drug.


Assuntos
Neoplasias Ovarianas/terapia , Quimioterapia Combinada , Estudos de Avaliação como Assunto , Feminino , Humanos , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/mortalidade , Neoplasias Ovarianas/radioterapia
5.
Breast Cancer Res Treat ; 5(2): 177-88, 1985.
Artigo em Inglês | MEDLINE | ID: mdl-2410072

RESUMO

Twenty-three patients with metastatic breast carcinoma were induced with a complex systemic therapy regimen in an attempt to ascertain if a complete remission rate greater than 50% could be obtained with intensive drug exposure. The durability of the remissions was observed by discontinuing therapy after 3 cycles in complete remission or after 6 cycles of treatment, whichever was longer. In 13 patients consolidation radiation therapy to the pre-treatment sites of disease was administered after discontinuing systemic therapy. Each 28 day cycle of the drug regimen consisted of pulses of adriamycin, vincristine, dibromodulcitol, prednisone, methotrexate with leukovorin rescue, hexamethylmelamine, bleomycin (discontinued after entry #17), fluoxymesterone, and tamoxifen. Eighteen of the 23 patients achieved complete remissions (78%) and 3 had partial remissions. The median times to treatment failure and survival were, respectively, 12.3 and 19.4 mos. The times for complete remission patients were, respectively, 13.5 and 23.9 mos. Consolidation radiotherapy at greater than or equal to 40 Gy to drug induced pre-study sites of complete remission was associated with first relapses at pre-study sites in 5/30 (17%) instances, compared to 21/35 (60%) in sites not receiving radiotherapy. Side-effects were commensurate with the intensity of the treatment program and are detailed in the text. Although the achievement of a high complete remission rate is promising, the failure to extend their duration beyond that of historical data suggests that additional conceptual and therapeutic approaches need to be explored.


Assuntos
Neoplasias da Mama/tratamento farmacológico , Altretamine/uso terapêutico , Antineoplásicos/efeitos adversos , Bleomicina/uso terapêutico , Neoplasias da Mama/patologia , Terapia Combinada , Doxorrubicina/uso terapêutico , Esquema de Medicação , Feminino , Fluoximesterona/uso terapêutico , Humanos , Leucovorina/uso terapêutico , Leucopenia/induzido quimicamente , Pulmão/efeitos da radiação , Metotrexato/uso terapêutico , Mitolactol/uso terapêutico , Metástase Neoplásica/tratamento farmacológico , Prednisona/uso terapêutico , Receptores de Estrogênio/análise , Tamoxifeno/uso terapêutico , Trombocitopenia/induzido quimicamente , Fatores de Tempo , Vincristina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa